Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym

Several analyst firms have revised price targets and estimates on shares of Corcept Therapeutics (Nasdaq: CORT) following news of FDA approval for its Korlym. Corcept shares last traded at $4.42, up more than 46 percent from Friday's closing price.

• JMP Securities - from $9 to $11, Market Outperform maintained
  
• Stifel Nicolaus - from $7 to $9, Buy maintained
  
• Ladenburg Thalmann - from $6 to $7, Buy maintained

Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Corcept.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
• Idex Corp. (IEX) Reiterated at Buy by Stifel